Pharmafile Logo

Spotlight on Saudi Arabia

August 25, 2015 | Saudi Arabia, emerging markets 

Published in eyeforpharma 20 May by Rachel Howard

What are the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom?

Traditionally the Middle East and North Africa (MENA) region has been overlooked by pharmaceutical companies, with the region contributing only about 2% of global pharmaceutical sales in 2010. Difficult regulatory environments and political turmoil have compounded the perceived lack of attractiveness of the region as a whole.

As we reach the middle of the decade, could the tide be turning? Over the last year, I have noticed increasing industry interest in Saudi Arabia (KSA) – and with good reason given it is the fastest growing pharmaceutical market in the Middle East, experiencing double-digit growth. In this article, I will take a look at the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom.

Background

Though vast swathes of the country are uninhabitable desert, Saudi Arabia has a population fast approaching 30 million. It is a young country, with over half of the population under 30 years of age. As it is home to the holy Islamic cities of Mecca and Medina, its population receives a seasonal boost as over two million pilgrims visit each year to perform the Hajj. It also contains about a quarter of the world’s known petroleum reserves, and oil revenues account for approximately 90 percent of the government’s income.

A key pillar of Saudi Arabia’s internal stability relative to much of the surrounding region has been the kingdom’s generous social welfare system, of which healthcare forms an important segment. Healthcare services are available free of charge not only to Saudi citizens but also to all pilgrims, regardless of their nationality. Recent decades have seen considerable improvement in both the quantity and quality of healthcare services. A Royal Decree in 2002 resulted in sizeable expansion of the primary care network. Care in the top public hospitals, such as Riyadh’s renowned King Fahad Medical City, easily rivals that of the West, with imported medical technology and state-of-the-art facilities. Medical education is also fully funded by the state, including overseas training. As a result, many physicians are trained in leading US and UK medical schools.

However, not all is rosy. Despite the country’s affluence and stated commitment to healthcare, indicators suggest Saudi Arabia’s overall healthcare performance remains mediocre compared with the West, with an infant mortality rate that is double the average and a shorter life expectancy.

Read the full article at http://www.researchpartnership.com/news/2015/05/spotlight-on-saudi-arabia/

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Article: The Art of Storytelling in Pharma Market Research

Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price...

The challenges of conducting effective pharmaceutical market research in emerging markets

Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets

“Most eye-catching” agency Pegasus scoops the ‘EMEA Healthcare PR Consultancy of the Year’ at Sabre Awards

Pegasus wins the prestigious “EMEA Healthcare PR Consultancy of the Year” award at the recent Sabre Awards in Berlin, organised by The Holmes Report.

Research Partnership appoints Director and Head of Business Analytics, North America

Tom has been appointed a Director in our Philadelphia office. He has over 25 years’ experience in healthcare research and has an extensive background in both quantitative and qualitative research,...

Article: The Art of Storytelling in Pharma Market Research

Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director

Event: EphMRA Annual Conference 2016

Frankfurt, Germany 21 - 23 June 2016

The challenges of conducting effective pharmaceutical market research in emerging markets

Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets

Blog: Viewing facility research, re-imagined

As technology has evolved, so too has the world of qualitative research

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high...